Denis Chem Lab Ltd
Incorporated in 1982, Denis Chem Lab Ltd does manufacturing of Pharmaceuticals Transfusion Solution in Bottles[1]
- Market Cap ₹ 111 Cr.
- Current Price ₹ 80.0
- High / Low ₹ 129 / 72.4
- Stock P/E 12.7
- Book Value ₹ 63.2
- Dividend Yield 1.87 %
- ROCE 13.9 %
- ROE 9.77 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 30.7%
Cons
- The company has delivered a poor sales growth of 5.03% over past five years.
- Promoter holding is low: 39.0%
- Company has a low return on equity of 11.9% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 67 | 75 | 98 | 112 | 107 | 123 | 135 | 109 | 136 | 161 | 167 | 173 | 176 | |
| 60 | 66 | 89 | 98 | 95 | 110 | 120 | 99 | 122 | 142 | 146 | 157 | 157 | |
| Operating Profit | 6 | 9 | 8 | 14 | 12 | 14 | 15 | 10 | 14 | 19 | 21 | 16 | 19 |
| OPM % | 9% | 12% | 9% | 12% | 11% | 11% | 11% | 9% | 11% | 12% | 13% | 9% | 11% |
| 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 2 | 3 | |
| Interest | 3 | 5 | 7 | 6 | 5 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 4 |
| Depreciation | 1 | 4 | 6 | 7 | 6 | 6 | 7 | 6 | 6 | 8 | 7 | 7 | 5 |
| Profit before tax | 2 | 0 | -3 | 2 | 2 | 6 | 6 | 3 | 9 | 11 | 15 | 11 | 12 |
| Tax % | 41% | 78% | 30% | 37% | -5% | -7% | 26% | 27% | 30% | 28% | 26% | 27% | |
| 1 | 0 | -4 | 1 | 2 | 6 | 4 | 2 | 6 | 8 | 11 | 8 | 9 | |
| EPS in Rs | 1.17 | 0.07 | -4.16 | 0.89 | 1.54 | 4.58 | 3.03 | 1.63 | 4.51 | 5.66 | 8.04 | 5.82 | 6.28 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 22% | 0% | 46% | 33% | 35% | 31% | 26% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 5% |
| 3 Years: | 8% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 59% |
| 5 Years: | 14% |
| 3 Years: | 9% |
| TTM: | -14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 16% |
| 3 Years: | 4% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 10% |
| 3 Years: | 12% |
| Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 9 | 9 | 12 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 6 | 8 | 7 | 18 | 36 | 43 | 45 | 48 | 53 | 58 | 66 | 71 | 74 |
| 31 | 48 | 44 | 37 | 25 | 23 | 14 | 9 | 3 | 2 | 1 | 1 | 8 | |
| 12 | 17 | 24 | 27 | 26 | 26 | 25 | 22 | 27 | 25 | 28 | 26 | 28 | |
| Total Liabilities | 52 | 81 | 85 | 94 | 101 | 106 | 97 | 92 | 96 | 99 | 109 | 112 | 124 |
| 9 | 42 | 40 | 44 | 40 | 50 | 46 | 41 | 42 | 35 | 38 | 39 | 36 | |
| CWIP | 9 | 0 | 10 | 1 | 5 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 34 | 39 | 35 | 49 | 56 | 55 | 52 | 51 | 55 | 62 | 72 | 73 | 85 | |
| Total Assets | 52 | 81 | 85 | 94 | 101 | 106 | 97 | 92 | 96 | 99 | 109 | 112 | 124 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2 | 14 | 21 | 7 | 11 | 8 | 13 | 8 | 17 | 16 | 18 | 12 | |
| -9 | -28 | -13 | -1 | -16 | -2 | -2 | -1 | -10 | -11 | -15 | -8 | |
| 12 | 13 | -7 | -0 | 1 | -5 | -14 | -6 | -7 | -4 | -4 | -4 | |
| Net Cash Flow | 0 | -1 | 1 | 5 | -4 | 1 | -3 | 1 | -0 | 1 | -1 | -0 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91 | 123 | 85 | 104 | 105 | 106 | 94 | 110 | 85 | 71 | 69 | 65 |
| Inventory Days | 37 | 40 | 39 | 35 | 52 | 50 | 51 | 60 | 50 | 39 | 43 | 37 |
| Days Payable | 53 | 81 | 119 | 136 | 150 | 102 | 108 | 103 | 99 | 79 | 90 | 81 |
| Cash Conversion Cycle | 75 | 81 | 4 | 3 | 8 | 55 | 37 | 67 | 36 | 31 | 22 | 21 |
| Working Capital Days | 32 | -19 | -57 | -13 | 4 | 17 | 32 | 63 | 51 | 41 | 37 | 38 |
| ROCE % | 16% | 11% | 5% | 12% | 9% | 11% | 11% | 6% | 14% | 16% | 20% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Copy of Newspaper Publication regarding the special window for Re-lodgement of transfer request of physical shares.
-
Results-Financial Results For December 31, 2025
14 Feb - Unaudited Q3 FY26 results: revenue Rs4,551.83L, profit Rs332.16L; board approved 14 Feb 2026.
-
Board Meeting Outcome for Submission Of Unaudited Financial Results For The Quarter Ended On 31St December, 2025
14 Feb - Unaudited Q3 (31 Dec 2025): Revenue Rs4,551.83L; Profit Rs332.16L; EPS Rs2.39; Board approved Feb 14, 2026.
-
Board Meeting Intimation for Taking On Record Unaudited Financial Results For The Quarter Ended On 31St December, 2025
4 Feb - Board meeting Feb 14, 2026 to approve unaudited results for quarter ended Dec 31, 2025; trading window closed.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Jan
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
DCLL manufactures and markets sterile Intravenous injectibles in Glass and Plastic Bottles for human and veterinary consumption. It also manufactures products on contract basis for multinational pharmaceutical companies who market them under their own brands. Company has a fully equipped in-house Quality Control Laboratory having different interdepartments for Chemical Testing, Physico-Chemical Testing, Microbiological Testing, Pyrogens Testing, Sterility Testing and Toxicity Testing. All raw materials, packaging materials, in process testing and finished stocks are tested in-house.